300 Technology Square, 8th Floor
About Frequency TherapeuticsFrequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone. Our platform technology is founded on discoveries in progenitor cell biology by Bob Langer, Sc.D. at MIT and Jeff Karp, Ph.D., at Harvard, with contributions from Xiaolei Yin, Ph.D. and other members of the Karp Lab at Harvard and Brigham & Women's Hospital.
Co-founder and CEO: David Luccino
Co-founder and CSO: Chris Loose, Ph.D.
Co-founder and Vice President, Biology and Regenerative Medicine: Will Mclean, Ph.D.
COO: Michael Jirousek, Ph.D.
CMO: Peter C. Weber, M.D., M.B.A.
Senior Vice President, Drug Development and Technical Operations: Raj Manchanda, Ph.D.
Please click here for Frequency Therapeutics' technology.
32 articles with Frequency Therapeutics
Frequency Therapeutics Commences Dosing in its Phase 2a Study of FX-322 for Sensorineural Hearing Loss; FDA Grants FX-322 Fast Track Designation
FX-322 is being developed for the treatment of sensorineural hearing loss (SNHL), the most common type of hearing loss.
Frequency Therapeutics, Inc. announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $14.00 per share, for total gross proceeds of approximately $84.0 million, before deducting underwriting discounts and commissions.
8/23/2019Biopharma companies strengthen their senior leadership teams and boards of directors with this week's appointments.
Frequency Therapeutics, Inc., a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced new appointments to its leadership team.
Frequency Therapeutics announced the closing of a $62.0 million Series C financing.
Astellas and Frequency Therapeutics Enter into License Agreement for FX-322, a Regenerative Treatment Candidate for Hearing Loss
Astellas Obtains the Exclusive Rights to Develop and Commercialize FX-322 in Ex-U.S. Markets; Frequency Retains U.S. Rights
There’s been quite a few small and mid-sized deals announced today. Let’s take a look at four of them.
Preliminary clinical data suggests improvement on measures of hearing function
Frequency Therapeutics announced the addition of Glenn Dubin to the Company’s Board of Directors.
1/29/2019The Massachusetts Biotechnology Council (MassBio) is taking the lead in fostering the next generation of life science leaders in the Bay State with Project Onramp, an internship program that matches talented students from low-income backgrounds with paid internships in the state’s vibrant life sc...
Joel Marcus, Executive Chairman and Founder of Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments, and Michael Huang, Managing Partner at Taiwania Capital Management, join Board of Directors
Frequency Therapeutics today announced that the Company will present at the upcoming 37th Annual JP Morgan Healthcare Conference in San Francisco on Monday, January 7, 2019
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
After negative reports about after-hours parties that have been deemed disrespectful toward women, and multiple reports about the lack of gender diversity on industry boards of directors, biotech’s biggest trade association is taking action.
Frequency Therapeutics Completes Enrollment in Single Dose Safety Trial to Evaluate FX-322, a First-in-Class Drug Candidate for Hearing Restoration
Frequency Therapeutics today announced the completion of enrollment in the single dose safety trial to evaluate FX-322, a first-in-class drug candidate for hearing restoration from the company’s Progenitor Cell Activation (PCA) Regeneration platform.
Frequency Therapeutics Strengthens Scientific Advisory Board with Addition of Leading Experts in Neurology, Stem Cell and Regenerative Medicine
Robin Franklin, Ph.D., Professor of Stem Cell Medicine at the Wellcome Trust-MRC Cambridge Stem Cell Institute, and Sheng Ding, Ph.D., William K. Bowes, Jr. Distinguished Investigator and Professor at Gladstone Institute
Frequency Therapeutics Initiates Phase 1/2 Single Dose Clinical Trial to Evaluate FX-322, a First-in-Class Drug Candidate for Hearing Restoration
Trial marks the first time a potential progenitor cell activator will be tested in adult patients with stable sensorineural hearing loss
Research Award will support translational preclinical and early-stage clinical research to address hearing dysfunction resulting from military service-related injuries
Frequency Therapeutics to Lead Featured Session at the American Academy of Audiology Annual Conference
Frequency Therapeutics will lead a Featured Session at the American Academy of Audiology (AAA) Annual Conference taking place April 18 to 21 in Nashville, TN.
Science Magazine Recognizes Frequency Therapeutics’ PCA Regeneration Technology as a Breakthrough in Regenerative Medicine
Frequency Co-founder Will McLean, Ph.D., Named a Finalist Awardee for the Sartorius & Science Prize for Regenerative Medicine & Cell Therapy